In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, we see a flurry of M&A activity, key regulatory approvals, and significant pipeline developments. Meanwhile, the global pharma landscape is also being shaped by important market, pricing, and policy signals.
M&A and Strategic Deals
- Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05 billion marks a significant expansion in their oncology portfolio. Read more →
- Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics is set to boost their metabolic disease treatment offerings. Read more →
Regulatory and Approvals
- Arrowhead’s Redemplo received FDA approval, marking a significant advancement in gene therapy. Read more →
- Regeneron secured FDA approvals for Eylea HD, potentially strengthening its position in the eye care market. Read more →
Pipeline and R&D Highlights
- Pfizer’s mRNA flu shot has shown superior efficacy in trials, potentially reshaping the flu vaccine market. Read more →
- Roche’s Giredestrant has shown promise in a breast cancer study, potentially offering a new treatment option. Read more →
Market, Pricing and Policy Signals
- Amgen’s decision to cut the price of Repatha by 60% in the U.S. signals a strategic shift in response to market pressures. Read more →
- The FDA’s launch of a domestic generic drug fast-track review program could significantly impact the generic drug market. Read more →
Stay updated — follow PharmaSignal on LinkedIn and visit PharmaSignal.com for daily global pharma insights.